Benitec Biopharma Ltdadr (BNTC) SEC Filing 6-K Foreign Issuer report for the period ending Monday, September 30, 2019

Benitec Biopharma Ltdadr

CIK: 1552795

View differences made from one to another to evaluate Benitec Biopharma Ltdadr's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Benitec Biopharma Ltdadr.


Assess how Benitec Biopharma Ltdadr's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Benitec Biopharma Ltdadr's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Benitec Biopharma Ltdadr provided additional information to their SEC Filing as exhibits

CIK: 1552795
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001193125-19-258712
Submitted to the SEC: Mon Sep 30 2019 3:21:07 PM EST
Accepted by the SEC: Mon Sep 30 2019
Period: Monday, September 30, 2019
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink: